Information for your health

A study found Amgen Inc's experimental drug denosumab reduced the risk of osteoporosis and fracture in men receiving treatments for prostate cancer that can cause bone loss, the company said Monday.

The study of more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation treatment showed denosumab rendered greater increase in bone mineral density than a placebo. The increase was seen at the Lumbar spine and non-vertebral sites.